Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety evaluation of long-term oral NMN in healthy adult men
jRCTs031180242Phase 2Completed
- Sponsor
- Oriental Yeast
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nicotinamide mononucleotide, sponsored by Oriental Yeast. Primary endpoint: Safety of long-term oral NMN administration. Started Aug 2019; status: completed.
02
Drugs
nicotinamide mononucleotide
Beyond the preview
Go deeper on jRCTs031180242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180242.